$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

$nwbo Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000114420416100593 Filed on May 11, 2016

Income Statement

Concept	2016 Q1	2015 Q4	2015 Q1
Revenue	$240.0K	$863.0K	$194.0K
YoY Change	23.71%	-1.03%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.280M	$7.440M	$3.320M
YoY Change	28.92%	41.98%	-10.03%
% of Gross Profit
Research & Development	$13.44M	$44.81M	$19.63M
YoY Change	-31.52%	109.39%	-1.81%
% of Gross Profit
Depreciation & Amortization	$13.00K	$20.00K	$3.000K
YoY Change	333.33%	-105.88%
% of Gross Profit
Operating Expenses	$17.72M	$52.25M	$19.63M
YoY Change	-9.71%	96.13%	-1.81%
Operating Profit			-$22.83M
YoY Change			-3.59%
Interest Expense	$718.0K	$27.31M	$793.0K
YoY Change	-9.46%	-257.77%	550.0%
% of Operating Profit
Other Income/Expense, Net		$27.31M	-$23.60M
YoY Change		-258.22%	5.56%
Pretax Income	-$6.110M	-$24.08M	-$46.43M
YoY Change	-86.84%	-43.59%	0.85%
Income Tax
% Of Pretax Income
Net Earnings	-$6.106M	-$24.08M	-$46.43M
YoY Change	-86.85%	-43.59%	0.85%
Net Earnings / Revenue	-2544.17%	-2790.03%	-23934.54%
Basic Earnings Per Share		-$0.27	-$0.67
Diluted Earnings Per Share	-$62.54K	-$0.27	-$0.67
COMMON SHARES
Basic Shares Outstanding	101.7M shares		70.31M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2015 Q4	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.69M	$21.81M	$3.170M
YoY Change	268.77%	62.88%	-74.08%
Cash & Equivalents	$11.69M	$21.81M	$3.170M
Short-Term Investments
Other Short-Term Assets	$1.820M	$2.290M	$1.550M
YoY Change	17.42%	81.75%	933.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$13.50M	$24.10M	$4.715M
YoY Change	186.32%	64.6%	-61.91%
LONG-TERM ASSETS
Property, Plant & Equipment	$48.36M	$476.0K	$41.39M
YoY Change	16.85%	-98.81%	51632.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$153.0K	$190.0K	$55.00K
YoY Change	178.18%	245.45%	-8.33%
Total Long-Term Assets	$48.73M	$46.70M	$44.70M
YoY Change	9.01%	11.68%	34283.08%
TOTAL ASSETS
Total Short-Term Assets	$13.50M	$24.10M	$4.715M
Total Long-Term Assets	$48.73M	$46.70M	$44.70M
Total Assets	$62.23M	$70.80M	$49.41M
YoY Change	25.93%	25.4%	294.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.726M	$11.72M	$9.744M
YoY Change	-10.45%	19.29%	47.19%
Accrued Expenses	$1.189M	$1.309M	$940.0K
YoY Change	26.49%	8.09%	23.68%
Deferred Revenue
YoY Change
Short-Term Debt	$930.0K	$930.0K	$930.0K
YoY Change	0.0%	0.0%	0.0%
Long-Term Debt Due	$11.14M	$11.33M	$240.0K
YoY Change	4541.67%	77.86%	0.0%
Total Short-Term Liabilities	$57.81M	$64.79M	$90.97M
YoY Change	-36.45%	-13.62%	108.79%
LONG-TERM LIABILITIES
Long-Term Debt	$10.61M	$10.54M	$29.00M
YoY Change	-63.41%	-35.65%
Other Long-Term Liabilities		$141.0K	$148.0K
YoY Change		43.88%
Total Long-Term Liabilities	$10.61M	$10.54M	$29.14M
YoY Change	-63.59%	-36.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$57.81M	$64.79M	$90.97M
Total Long-Term Liabilities	$10.61M	$10.54M	$29.14M
Total Liabilities	$68.42M	$75.47M	$120.1M
YoY Change	-43.04%	-17.5%	175.68%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock		$630.7M	$496.5M
YoY Change		29.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.190M	-$4.676M	-$70.70M
YoY Change
Total Liabilities & Shareholders Equity	$62.23M	$70.80M	$49.41M
YoY Change	25.94%	25.4%	294.99%

Cashflow Statement

Concept	2016 Q1	2015 Q4	2015 Q1
OPERATING ACTIVITIES
Net Income	-$6.106M	-$24.08M	-$46.43M
YoY Change	-86.85%	-43.59%	0.85%
Depreciation, Depletion And Amortization	$13.00K	$20.00K	$3.000K
YoY Change	333.33%	-105.88%
Cash From Operating Activities	-$17.60M	-$23.23M	-$17.58M
YoY Change	0.07%	24.89%	66.51%
INVESTING ACTIVITIES
Capital Expenditures	-$2.680M	-$2.740M	$1.133M
YoY Change	-336.54%	-75.96%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities	-$2.408M	-$2.740M	-$1.133M
YoY Change	112.53%	-75.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$9.244M	41.37M	$8.510M
YoY Change	8.63%	-1.45%	98.37%
NET CHANGE
Cash From Operating Activities	-$17.60M	-23.23M	-$17.58M
Cash From Investing Activities	-$2.408M	-2.740M	-$1.133M
Cash From Financing Activities	$9.244M	41.37M	$8.510M
Net Change In Cash	-$10.76M	15.40M	-$10.21M
YoY Change	5.43%	28.44%	62.79%
FREE CASH FLOW
Cash From Operating Activities	-$17.60M	-$23.23M	-$17.58M
Capital Expenditures	-$2.680M	-$2.740M	$1.133M
Free Cash Flow	-$14.92M	-$20.49M	-$18.72M
YoY Change	-20.3%	184.58%	77.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21813000	USD
CY2016Q1	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	214000	USD
CY2015Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	349000	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	153000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	190000	USD
CY2016Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	48727000	USD
CY2016Q1	us-gaap	Assets Assets	62226000	USD
CY2015Q4	us-gaap	Assets Assets	70797000	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	8726000	USD
CY2016Q1	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	6366000	USD
CY2015Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	5455000	USD
CY2016Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	185000	USD
CY2015Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	886000	USD
CY2016Q1	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	746000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	96000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	630613000	USD
CY2015Q4	nwbo	Development Stage Enterprise Deficit Accumulated During Development Stage1 DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage1	635262000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-123000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-4676000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	70797000	USD
CY2015Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	23025000	USD
CY2016Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	13525000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	793000	USD
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	194000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.67
CY2016Q1	us-gaap	Notes Payable Current NotesPayableCurrent	934000	USD
CY2015Q4	us-gaap	Notes Payable Current NotesPayableCurrent	934000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1309000	USD
CY2016Q1	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	6200000	USD
CY2015Q4	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	6200000	USD
CY2016Q1	nwbo	Development Stage Enterprise Deficit Accumulated During Development Stage1 DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage1	641368000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	377000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11721000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Mortgage Loans Held For Sale ProceedsFromSaleOfMortgageLoansHeldForSale	0	USD
CY2015Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	138000	USD
CY2016Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2015Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	185000	USD
CY2015Q1	us-gaap	Proceeds From Sale Of Mortgage Loans Held For Sale ProceedsFromSaleOfMortgageLoansHeldForSale	4997000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17595000	USD
CY2015Q1	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	1133000	USD
CY2016Q1	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	2683000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1133000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2408000	USD
CY2016Q1	nwbo	Accrued Interest Converted To Common Stock AccruedInterestConvertedToCommonStock	0	USD
CY2015Q1	nwbo	Stock And Warrants Issued To Related Party Expenses StockAndWarrantsIssuedToRelatedPartyExpenses	6359000	USD
CY2016Q1	nwbo	Stock And Warrants Issued To Related Party Expenses StockAndWarrantsIssuedToRelatedPartyExpenses	3644000	USD
CY2015Q1	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	279000	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1189000	USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	10950000	USD
CY2015Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	11144000	USD
CY2015Q1	us-gaap	Revenue From Grants RevenueFromGrants	194000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19625000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3400000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-22831000	USD
CY2015Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-23158000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	718000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-46433000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-6106000	USD
CY2015Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	349000	USD
CY2016Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-1434000	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	97688000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69406000	shares
CY2015Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	68000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-500000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46501000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5606000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	500000	USD
CY2016Q1	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-337000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-378000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-3116000	USD
CY2015Q1	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	103000	USD
CY2016Q1	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	912000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17582000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13390000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3170000	USD
CY2015Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3000	USD
CY2016Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13000	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	234000	USD
CY2016Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	209000	USD
CY2015Q1	nwbo	Accrued Interest Converted To Common Stock AccruedInterestConvertedToCommonStock	-349000	USD
CY2016Q1	nwbo	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	-37000	USD
CY2015Q1	nwbo	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	0	USD
CY2015Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3651000	USD
CY2016Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9244000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8510000	USD
CY2016Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	207000	USD
CY2015Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	321000	USD
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	70000	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	105000	USD
CY2016Q1	us-gaap	Notes Payable NotesPayable	1119000	USD
CY2015Q4	us-gaap	Notes Payable NotesPayable	1119000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	46009000	shares
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32678000	shares
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	27267441000	shares
CY2016Q1	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	16791000	shares
CY2016Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	42715146000	shares
CY2015Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	4.4
CY2016Q1	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	11.86
CY2016Q1	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	3.53
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	nwbo	Accrued Expenses Related Party AccruedExpensesRelatedParty	12000	USD
CY2015Q4	nwbo	Accrued Expenses Related Party AccruedExpensesRelatedParty	11000	USD
CY2016Q1	nwbo	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	50000	USD
CY2015Q4	nwbo	Convertible Notes Payable Related Parties Current ConvertibleNotesPayableRelatedPartiesCurrent	50000	USD
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2016Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	634000	USD
CY2015Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-15000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10125000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10220000	USD
CY2016Q1	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	-275000	USD
CY2015Q1	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0	USD
CY2016Q1	nwbo	Redeemable Security Settlement RedeemableSecuritySettlement	0	USD
CY2015Q1	nwbo	Redeemable Security Settlement RedeemableSecuritySettlement	299000	USD
CY2016Q1	us-gaap	Accrued Environmental Loss Contingencies Noncurrent AccruedEnvironmentalLossContingenciesNoncurrent	6200000	USD
CY2016Q1	us-gaap	Site Contingency Loss Exposure In Excess Of Accrual High Estimate SiteContingencyLossExposureInExcessOfAccrualHighEstimate	4500000	USD
CY2016Q1	us-gaap	Site Contingency Loss Exposure In Excess Of Accrual Low Estimate SiteContingencyLossExposureInExcessOfAccrualLowEstimate	32000000	USD
CY2016Q1	us-gaap	Site Contingency Loss Exposure In Excess Of Accrual Best Estimate SiteContingencyLossExposureInExcessOfAccrualBestEstimate	6200000	USD
CY2016Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	229000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	216000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	13000	USD
CY2015Q1	us-gaap	Depreciation Depreciation	3000	USD
CY2016Q1	us-gaap	Contractual Interest Expense On Prepetition Liabilities Not Recognized In Statement Of Operations ContractualInterestExpenseOnPrepetitionLiabilitiesNotRecognizedInStatementOfOperations	137000	USD
CY2015Q1	us-gaap	Contractual Interest Expense On Prepetition Liabilities Not Recognized In Statement Of Operations ContractualInterestExpenseOnPrepetitionLiabilitiesNotRecognizedInStatementOfOperations	216000	USD
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	101740440	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	101740440	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	95858087	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95858087	shares
CY2016Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; COLOR: #212121" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Use of Estimates</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 37.4pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, valuing environmental liabilities, estimating the fair value of equity instruments recorded as derivative liabilities, and estimating the useful lives of depreciable assets and whether impairment charges may apply.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q1	nwbo	Proceeds From Issuance Of Capital Stock And Warrants ProceedsFromIssuanceOfCapitalStockAndWarrants	10000000	USD
CY2015Q1	nwbo	Proceeds From Issuance Of Capital Stock And Warrants ProceedsFromIssuanceOfCapitalStockAndWarrants	0	USD
CY2016Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	756000	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2016Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	11700000	USD
CY2016Q1	nwbo	Current Assets Less Payables CurrentAssetsLessPayables	44300000	USD
CY2016Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	14500000	USD
CY2016Q1	nwbo	Convertible Notes Payable Related Parties ConvertibleNotesPayableRelatedParties	6400000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	48589000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	46373000	USD
CY2016Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	135000	USD
CY2015Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	135000	USD
CY2016Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	50000	USD
CY2015Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	50000	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	756000	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	5155000	USD
CY2016Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	8799000	USD
CY2015Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2016Q1	nwbo	Noncash Derivative Liability NoncashDerivativeLiability	44300000	USD
CY2016Q1	nwbo	Projected Potential Future Liability ProjectedPotentialFutureLiability	6200000	USD
CY2016Q1	us-gaap	Deferred Compensation Liability Current And Noncurrent DeferredCompensationLiabilityCurrentAndNoncurrent	8800000	USD
CY2016Q1	nwbo	Class Of Warrant Or Right Granted In Registered Direct Offering ClassOfWarrantOrRightGrantedInRegisteredDirectOffering	12058825000	shares
CY2016Q1	nwbo	Class Of Warrant Or Right Granted In Registerd Direct Offering Weighted Average Exercise Price ClassOfWarrantOrRightGrantedInRegisterdDirectOfferingWeightedAverageExercisePrice	3.04
CY2016Q1	nwbo	Procees From Sale Of Availiable Securities Gross ProceesFromSaleOfAvailiableSecuritiesGross	10000000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	9200000	USD
CY2016Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	10000000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5200000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6400000	USD
CY2016Q1	nwbo	Common Stock Shares And Warrants Issued Favored Nation Provision Terms CommonStockSharesAndWarrantsIssuedFavoredNationProvisionTerms	On March 3, 2016, the Company entered into a financing under which it sold 5.9 million common shares and 12.1 million Series A, B and C warrants to unrelated investors on terms more favorable than the existing terms of Cognates shares. The sale of common shares had an effective price of $1.7, which triggered a most favored nation obligation which would result in an obligation to issue 6.0 million shares to Cognate. However, these shares have not been issued, and the Company is in active negotiations with Cognate seeking to modify these arrangements.
CY2016Q1	nwbo	Accrued Exit Fee Incurred From Mortgage Loan AccruedExitFeeIncurredFromMortgageLoan	0	USD
CY2015Q1	nwbo	Accrued Exit Fee Incurred From Mortgage Loan AccruedExitFeeIncurredFromMortgageLoan	50000	USD
CY2016Q1	nwbo	Warrant Exercise On Warrant Liability WarrantExerciseOnWarrantLiability	0	USD
CY2015Q1	nwbo	Warrant Exercise On Warrant Liability WarrantExerciseOnWarrantLiability	520000	USD
CY2016Q1	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	0	USD
CY2015Q1	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	257000	USD
CY2016Q1	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2015Q1	us-gaap	Interest Paid Net InterestPaidNet	428000	USD
CY2016Q1	nwbo	Class Of Warrant Or Right Owed To Cognate Weighted Average Exercise Price ClassOfWarrantOrRightOwedToCognateWeightedAverageExercisePrice	1.70
CY2016Q1	nwbo	Class Of Warrant Or Right Owed To Cognate ClassOfWarrantOrRightOwedToCognate	3405671000	shares

Files In Submission

Name	View Source	Status
0001144204-16-100593-index-headers.html	Edgar Link	pending
0001144204-16-100593-index.html	Edgar Link	pending
0001144204-16-100593.txt	Edgar Link	pending
0001144204-16-100593-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nwbo-20160331.xml	Edgar Link	completed
nwbo-20160331.xsd	Edgar Link	pending
nwbo-20160331_cal.xml	Edgar Link	unprocessable
nwbo-20160331_def.xml	Edgar Link	unprocessable
nwbo-20160331_lab.xml	Edgar Link	unprocessable
nwbo-20160331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v439072_10q.htm	Edgar Link	pending
v439072_ex31-1.htm	Edgar Link	pending
v439072_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

2016 Q1 Form 10-Q Financial Statement

#000114420416100593 Filed on May 11, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NWBO NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

2016 Q1 Form 10-Q Financial Statement

#000114420416100593 Filed on May 11, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo